Currently out of the existing stock ratings of Gregory Renza, 162 are a BUY (82.23%), 35 are a HOLD (17.77%).

Gregory Renza

Work Performance Price Targets & Ratings Chart

Analyst Gregory Renza, currently employed at RBC, carries an average stock price target met ratio of 37.85% that have a potential upside of 32.24% achieved within 99 days.

Gregory Renza’s has documented 392 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VRDN, Viridian Therapeutics at 28-Aug-2024.

Wall Street Analyst Gregory Renza

Analyst best performing recommendations are on RXDX (PROMETHEUS BIOSCIENCES).
The best stock recommendation documented was for RXDX (PROMETHEUS BIOSCIENCES) at 12/7/2022. The price target of $111 was fulfilled within 1 day with a profit of $15.2 (15.87%) receiving and performance score of 158.66.

Average potential price target upside

of $40.37 (75.04%) on ITRM (ITERUM THERAPEUTICS PLC).
of $24.26 (17.54%) on SGEN (SEAGEN).
of $23.03 (29.35%) on INO (INOVIO PHARMACEUTICALS).

ACAD ACADIA Pharmaceuticals APRE Aprea Therapeutics APTO Aptose Biosciences AVTX Avalo Therapeutics BLU BELLUS Health . GMDA Gamida Cell Ltd INO Inovio Pharmaceuticals ITRM Iterum Therapeutics PLC MORF Morphic XNCR Xencor GBT Global Blood Therapeutics SGEN Seagen ADCT ADC Therapeutics SA RXDX Prometheus Biosciences VRCA Verrica Pharmaceuticals JAZZ Jazz Pharmaceuticals PLC AMGN Amgen IDYA Ideaya Biosciences LIFE aTyr Pharma NRIX Nurix Therapeutics NUVB Nuvation Bio PRVB Provention Bio SPRB Spruce Biosciences VIRX Viracta Therapeutics VSTM Verastem ARQL ArQule ALPN Alpine Immune Sciences CRMD CorMedix EXEL Exelixis PCRX Pacira Pharmaceuticals VRDN Viridian Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

David Hoang (CITI)